Afuco™ Anti-IGF1R ADCC Therapeutic Antibody (Cixutumumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
Supplier Creative Biolabs
Product # AFC-TAB-078
Pricing Inquiry
Host Human
Target IGF1R
Species Reactivity Human
Type ADCC enhanced antibody
Applications IF, IP, Neut, FuncS, ELISA, FC
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback